1. The plasma concentrations of agomelatine and its two metabolites are simultaneously determined by High performance liquid chromatography-tandem mass spectrometry; 2. The gene polymorphisms of CYP1A2, ABCB1 and CYP2C9 are detected by fluorescence in situ hybridization or fluorescence polymerase chain reaction; 3. The correlation of CYP1A2, ABCB1, CYP2C9 gene polymorphisms with the blood concentration of agomelatine and its two metabolites is investigated by pharmacokinetic study; 4. According to the correlation between the above genotypes and blood drug concentration, a lean medication guidance scheme for agomelatine will be formed.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Plasma concentration of Agomelatine
Timeframe: 3 hours after the patients take agomelatine
CYP1A2, ABCB1, and CYP2C9 genotypes
Timeframe: 3 hours after the patients take agomelatine
Plasma concentration of Agomelatine metabolites
Timeframe: 3 hours after the patients take agomelatine